FRANKFURT (Reuters) - German generic drugmaker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.
As part of the agreement in principle, with details yet to be hammered out, Stada will get exclusive marketing rights in Europe for generic oncology drugs developed and produced by Hetero. Stada will also get a sub-licence in further regions outside India and the United States.
The alliance covers cancer drugs that will lose patent protection between 2016 and 2020 and Stada will decide at a later stage whether Hetero compounds will also go its existing oncology drugs, Stada Chief Executive Hartmut Retzlaff said at a press conference.
Financial terms were not provided.
(Reporting by Ludwig Burger; Editing by Georgina Prodhan)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app